Antares Pharma Incorporated
0 DAYS LEFT TO SEEK LEAD PLAINTIFF STATUS
|Company Name:||Antares Pharma Incorporated|
|Stock Symbol :||NASDAQ: ATRS|
|Class Period Start:||12/21/2016|
|Class Period End:||10/12/2017|
|Lead Plaintiff motion:||12/22/2017|
|Type of Case:||Securities Class Action|
|Court:||U.S. District Court for the District of New Jersey|
Thieler Law Corp advises investors with losses exceeding $100,000 of the December 22, 2017 lead plaintiff deadline in a class action lawsuit filed against Antares Pharma Inc (NASDAQ: ATRS) (“Antares” or “the Company”). The suit is pending in the U.S. District Court for the District of New Jersey and investors, who purchased Antares Pharma Inc securities between December 21, 2016, and October 12, 2017, have until December 22, 2017 to move for lead plaintiff. You do not need to move for lead plaintiff to be a member of the Class.
If you purchased Antares Pharma Inc securities during the Class Period, and have losses over $100,000, you may contact Thieler Law Corp by calling at (619) 377 - 4324 or emailing email@example.com . No class has been certified in this case, and if your losses are less than $100,000 you are still a member of the class.
The complaint alleges that during the Class Period defendants made false and misleading statements and/or allegedly failed to disclose that Antares had provided insufficient data to the U.S. Food and Drug Administration in connection with its New Drug Application for Xyosted; as a result, Antares had overstated the approval prospects for Xyosted; consequently, Antares’s public statements were materially false and misleading at all relevant times.
On October 12, 2017, the Company revealed that on October 11, 2017, it had received a letter from the FDA stating that the agency had "identified deficiencies that preclude the continuation of the discussion of labeling and post marketing requirements/commitments" for Xyosted.
Follwing this news, NASDAQ: ATRS fell $1.41, or 37.80%, to close at $2.32 on October 13, 2017.
On October 20, 2017, the Company disclosed receipt of a Complete Response Letter ("CRL") from the FDA regarding the NDA for Xyosted, "indicating that the FDA cannot approve the NDA in its present form." Antares stated, in part that "the FDA is concerned that XYOSTED could cause a clinically meaningful increase in blood pressure" and also "raised a concern regarding the occurrence of depression and suicidality."
If you were negatively impacted by your investment in Antares Pharma Inc securities between December 21, 2016, and October 12, 2017 and would like to learn more about this lawsuit and your ability to participate as a lead plaintiff, please contact us for your no-cost evaluation.
Thieler Law Corp purchases advertisements on search engines, social media sites and other websites. If you send us information, note that does not create an attorney-client relationship with the firm.
Thieler Law Corp
2534 State Street - Suite 406,
San Diego, CA 92101
telephone at +1 (619) 377 - 4324
visit our website http://www.thielerlaw.com/
Facsimile: +1 (619) 785 – 3185